INmune Bio Inc. (INMB)
undefined
undefined%
At close: undefined
4.75
-0.46%
After-hours Dec 13, 2024, 04:00 PM EST

Company Description

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease.

The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.

Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease.

The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London.

INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

INmune Bio Inc.
INmune Bio Inc. logo
Country United States
IPO Date Feb 4, 2019
Industry Biotechnology
Sector Healthcare
Employees 11
CEO Dr. Raymond Joseph Tesi M.D.

Contact Details

Address:
225 NE Mizner Boulevard
Boca Raton, Florida
United States
Website https://www.inmunebio.com

Stock Details

Ticker Symbol INMB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001711754
CUSIP Number 45782T105
ISIN Number US45782T1051
Employer ID 47-5205835
SIC Code 2836

Key Executives

Name Position
Dr. Raymond Joseph Tesi M.D. Co-Founder, President, Chief Executive Officer, Chief Medical Officer & Chairman
David J. Moss M.B.A. Chief Financial Officer, Treasurer & Secretary
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. Chief Scientific Officer & Chief Manufacturing Officer
Joshua S. Schoonover Esq. General Counsel

Latest SEC Filings

Date Type Title
Dec 09, 2024 8-A12B/A [Amend] Filing
Dec 09, 2024 8-K Current Report
Dec 09, 2024 4 Filing
Dec 09, 2024 4 Filing
Dec 09, 2024 4 Filing
Dec 09, 2024 4 Filing
Dec 09, 2024 4 Filing
Dec 09, 2024 4 Filing
Dec 09, 2024 4 Filing
Nov 14, 2024 8-K Current Report